SLN Silence Therapeutics plc

MIXED Impact: 6/10 8-K
Horizon months Filed Mar 5, 2026 Processed 2mo ago SEC 0001193125-26-092578
8-K Item 2.02: Earnings release
Latest settled — T+20d
SLN ▲ +8.00% at T+20d
NEUTRAL call ✓ call won +8.00% · α vs SPY +11.79% · entry $5.50 → $5.94
Next anchor: T+60d in 8d
Last close $6.20 (close May 22) · +12.73% from $5.50 entry
Entry anchored
Mar 4, 03:59 PM ET
via Databento tick
T+1d
+13.27%
call +13.27% · α +14.59%
$6.23
settled 3mo ago
T+5d
+26.73%
call +26.73% · α +28.96%
$6.97
settled 2mo ago
T+20d
+8.00%
call +8.00% · α +11.79%
$5.94
settled 7w ago
T+60d
—
call — · α —
—
in 8d

Price Chart

Loading chart...

Executive Summary

Silence Therapeutics reported a significant year-over-year decline in revenue and increased net loss, driven by the conclusion of prior collaborations. However, the company highlighted positive clinical progress, including accelerated topline results for its divesiran trial in polycythemia vera expected in Q3 2026, and promising preclinical data for new siRNA programs. The cash position of $85.1 million provides runway for ongoing development.

Key Financial Metrics

Revenue
$559.0K
-98.7% YoY
EPS
$-63.00

Actionable Insight

Monitor the upcoming topline results from the Phase 2 SANRECO trial in Q3 2026, which could be a major value driver. The company's ability to secure partnerships for its Phase 3-ready zerlasiran program and advance its preclinical pipeline will be key indicators of future success. The cash position appears sufficient to fund operations through the near-term catalysts.

Key Facts

  • Revenue dropped 98.7% YoY to $0.6 million due to conclusion of Hansoh collaboration and reduced AstraZeneca revenue
  • Net loss increased 95.5% YoY to $88.6 million
  • Cash position of $85.1 million as of December 31, 2025
  • Topline results for Phase 2 SANRECO trial of divesiran in polycythemia vera expected in Q3 2026 (accelerated from H2 2026)
  • AstraZeneca will not pursue further development of SLN312 beyond Phase 1, with rights reverting to Silence
  • Generated promising preclinical data for SLN365 (GPR146) and SLN098 (INHBE) programs

Financial Impact

Revenue decreased by $42.7 million year-over-year, while net loss increased by $43.3 million

revenuenet losscash position

Risk Factors

  • High cash burn rate with increasing net losses
  • Dependence on successful clinical trial outcomes
  • Need to secure partnerships or additional funding for later-stage development

Market Snapshot

Exchange
OTC

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-092578
Document: sln-20260305.htm0001193125-26-092578
Document: sln-ex99_2.htm0001193125-26-092578
Document: 0001193125-26-092578-index-headers.html0001193125-26-092578
Document: 0001193125-26-092578-index.html0001193125-26-092578
Document: 0001193125-26-092578.txt0001193125-26-092578

US Market Status

Market Closed — Opens Tue (34h 50m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access